{
  "actions": [
    {
      "acted_at": "2022-05-03",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2022-05-03",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr7640-117",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    }
  ],
  "congress": "117",
  "cosponsors": [
    {
      "bioguide_id": "B001251",
      "district": "1",
      "name": "Butterfield, G. K.",
      "original_cosponsor": true,
      "sponsored_at": "2022-05-03",
      "state": "NC",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2022-05-03",
  "number": "7640",
  "official_title": "To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as \"orphan drugs\").",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "s4348-117",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    }
  ],
  "short_title": null,
  "sponsor": {
    "bioguide_id": "B001257",
    "district": "12",
    "name": "Bilirakis, Gus M.",
    "state": "FL",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2022-05-03",
  "subjects": [
    "Health"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2022-05-03",
    "date": "2022-09-20T17:31:24Z",
    "text": "This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as \"orphan drugs\").",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as \"orphan drugs\").",
      "type": "official"
    }
  ],
  "updated_at": "2023-03-08T19:58:48Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/117/hr/BILLSTATUS-117hr7640.xml"
}